

# CITATION REPORT

List of articles citing

## Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

DOI: 10.1155/2015/460190

BioMed Research International, 2015, 2015, 460190.

**Source:** <https://exaly.com/paper-pdf/61077585/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
103	Non-alcoholic fatty liver disease-From the cardiologist perspective. <b>2016</b> , 16, 534-41		9
102	Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. <b>2016</b> , 2016, 6420408		3
101	Metabolic aspects of adult patients with nonalcoholic fatty liver disease. <b>2016</b> , 22, 7006-16		107
100	Hedgehog signaling is a potent regulator of liver lipid metabolism and reveals a GLI-code associated with steatosis. <b>2016</b> , 5,		48
99	Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress. <b>2016</b> , 361-362, 39-48		15
98	Normal weight dyslipidemia: Is it all about the liver?. <b>2016</b> , 24, 556-67		26
97	Kcne2 deletion causes early-onset nonalcoholic fatty liver disease via iron deficiency anemia. <b>2016</b> , 6, 23118		10
96	Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. <b>2016</b> , 61, 1356-64		85
95	Clinical Applications and Systems Biomedicine. <b>2016</b> , 323-335		
94	Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study. <b>2016</b> , 65, 784-790		36
93	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. <b>2016</b> , 36, 1563-1579		96
92	Devilish Effects of Taz in Nonalcoholic Steatohepatitis. <b>2016</b> , 24, 771-772		3
91	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. <b>2016</b> , 8, 75-84		19
90	Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. <b>2016</b> , 65, 668-670		15
89	Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. <b>2016</b> , 150, 1208-1218		61
88	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?. <b>2016</b> , 10, 229-42		32
87	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 150, 1811-1822.e4		69

86	Pathogenesis of nonalcoholic steatohepatitis. <b>2016</b> , 73, 1969-87	111
85	Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease. <b>2017</b> , 49, 523-529	7
84	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <b>2017</b> , 37, 1389-1396	26
83	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <b>2017</b> , 131, 1301-1315	38
82	TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. <b>2017</b> , 65, 1526-1542	47
81	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage. <b>2017</b> , 257, 232-239	29
80	Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats. <b>2017</b> , 7, 13167	7
79	The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. <b>2017</b> , 7, 9273	14
78	Editorial: new insights into the relationship between the intestine and non-alcoholic fatty liver-is "fatty gut" involved in disease progression?. <b>2017</b> , 46, 377-378	4
77	Metabolism disrupting chemicals and metabolic disorders. <b>2017</b> , 68, 3-33	500
76	Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 9,	47
75	Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease. <b>2018</b> , 38, 1832-1838	2
74	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	30
73	NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. <b>2018</b> , 27, 2214-2223	65
72	Valoraci3n de la enfermedad por h3gado graso no alcoh3lico desde el laboratorio cl3nico. <b>2018</b> , 11, 163-173	
71	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <b>2018</b> , 283, 356-370	140
70	Etiology and Pathogenesis of Hepatocellular Carcinoma. <b>2018</b> , 1-15	2
69	Coding variants in and are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist. <b>2018</b> , 2, 561-570	11

68	Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients. <b>2018</b> , 48, E162-E171	6
67	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2018</b> , 22, 1-10	56
66	Genetics and epigenetics of NAFLD and NASH: Clinical impact. <b>2018</b> , 68, 268-279	362
65	The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin pегlispro. <b>2018</b> , 18, 487-493	9
64	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. <b>2018</b> , 19,	70
63	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. <b>2018</b> , 8, 14297	72
62	Management of Nonalcoholic Fatty Liver Disease (NAFLD). <b>2018</b> ,	
61	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <b>2018</b> , 2, 666-675	30
60	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	1
59	Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?. <b>2018</b> , 1061, 63-77	4
58	Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <b>2018</b> , 48, 451-459	13
57	New insights into ANGPTL3 in controlling lipoprotein metabolism and risk of cardiovascular diseases. <b>2018</b> , 17, 12	16
56	Hepatic Fibrogenesis. <b>2018</b> , 82-92	1
55	Clinical Application of Stem Cells in Liver Diseases: From Bench to Bedside. <b>2018</b> , 317-346	
54	Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. <b>2019</b> , 20,	9
53	Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. <b>2019</b> , 25, 3009-3020	47
52	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. <b>2019</b> , 11,	42
51	Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. <b>2019</b> , 20,	16

50	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. <b>2019</b> , 282, 110-120	45
49	Bioinformatics Analysis of Key Differentially Expressed Genes in Nonalcoholic Fatty Liver Disease Mice Models. <b>2018</b> , 19, 25-35	9
48	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. <b>2019</b> , 18, 466-471	21
47	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <b>2019</b> , 60, 1144-1153	27
46	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <b>2019</b> , 9, 3682	42
45	PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. <b>2019</b> , 1-7	5
44	Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. <b>2019</b> , 25, 56-67	26
43	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. <b>2019</b> , 39, 250-256	22
42	PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. <b>2020</b> , 40, 107-119	46
41	Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). <b>2020</b> , 80, 106-113	13
40	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. <b>2020</b> , 57, 102866	17
39	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. <b>2020</b> , 11,	1
38	CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver. <b>2020</b> , 7, 583943	3
37	APOC3rs2854116, PNPLA3rs738409, and TM6SF2rs58542926 polymorphisms might influence predisposition of NAFLD: A meta-analysis. <b>2020</b> , 72, 1757-1764	3
36	Nutrition and Genetics in NAFLD: The Perfect Binomium. <b>2020</b> , 21,	26
35	Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. <b>2020</b> , 5, 49	7
34	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. <b>2021</b> , 116, 154457	19
33	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. <b>2021</b> , 27, 64-72	2

32	PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. <b>2021</b> , 11,	1
31	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. <b>2021</b> , 117, 154708	19
30	PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center. <b>2021</b> ,	2
29	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <b>2021</b> ,	3
28	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. <b>2021</b> , 6, 1036-1046	0
27	Genetics Is of the Essence to Face NAFLD. <b>2021</b> , 9,	7
26	Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis. <b>2021</b> , 100, e24277	1
25	Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. <b>2019</b> , 129, 4885-4900	26
24	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. <b>2020</b> , 7, HEP36	4
23	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. <b>2020</b> , 1, 218-243	3
22	and polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. <b>2020</b> , 12, 792-806	7
21	Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. <b>2020</b> , 12, 1228-1238	2
20	Liver Mitochondrial DNA Copy Number and Deletion Levels May Contribute to Nonalcoholic Fatty Liver Disease Susceptibility. <b>2016</b> , 16, e40774	16
19	Metabolic effects of risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 inform about heterogeneity of non-alcoholic fatty liver disease.	
18	SPECIFIC FEATURES OF METABOLIC DISORDERS IN MALES AND FEMALES WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <b>2020</b> , 6, 18-32	
17	Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease. <b>2020</b> , 183, 62-69	
16	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <b>2021</b> ,	6
15	models for non-alcoholic fatty liver disease: Emerging platforms and their applications.. <b>2022</b> , 25, 103549	3

14	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. <b>2022</b> , 2, 30-76	1
13	Single Nucleotide Polymorphism of Genes Associated with Metabolic Fatty Liver Disease.. <b>2022</b> , 2022, 9282557	1
12	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <b>2022</b> , 94, 216-253	5
11	Platelets in Non-alcoholic Fatty Liver Disease.. <b>2022</b> , 13, 842636	1
10	Presentation_1.PPTX. <b>2020</b> ,	
9	African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. <b>2022</b> , 100728	0
8	Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease. <b>2022</b> ,	
7	The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. 13,	2
6	Nonalcoholic fatty liver disease and diabetes. <b>2022</b> , 13, 668-682	0
5	One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes. <b>2022</b> , 2, 243-257	0
4	Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. <b>2022</b> , 32, 104-140	1
3	Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. 13,	0
2	Psychiatric Aspects of Obesity in Transplantation. <b>2022</b> , 65-72	0
1	Genetic variation in TBC1 domain family member 1 gene associates with the risk of lean NAFLD via high-density lipoprotein. 13,	0